Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Durect Corp
(NQ:
DRRX
)
0.8300
USD
-0.0020 (-0.24%)
Official Closing Price
/ Updated:
4:00 PM EDT, Jun 19, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Durect Corp
< Previous
1
2
3
4
5
6
7
Next >
Free Research Reports on DRRX, GPS, JASO and PCLN Issued by the Bedford Report
May 13, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit
Read More
from
Marketwired News Releases
DURECT Announces Update on Remoxy®
May 10, 2013
from
PR Newswire
DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
May 02, 2013
from
PR Newswire
Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial
May 02, 2013
Initiates Efforts to Secure Strategic Development and Commercialization Partner
Read More
from
GlobeNewswire News Releases
Free Research Reports on CYH, DRRX, SU and UBS Issued by the Paragon Report
May 01, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit
Read More
from
Marketwired News Releases
Pain Therapeutics Reports Q1 2013 Financial Results
April 24, 2013
from
GlobeNewswire News Releases
DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
April 24, 2013
from
PR Newswire
DURECT Announces Submission of New Drug Application for POSIDUR™ (SABER®-Bupivacaine)
April 16, 2013
from
PR Newswire
DURECT Corporation Announces Fourth Quarter 2012 Financial Results and Update of Programs
February 28, 2013
from
PR Newswire
DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
February 22, 2013
from
PR Newswire
Pain Therapeutics Reports 2012 Financial Results
February 06, 2013
Innovation, Disciplined Spending Expected in 2013
Read More
from
GlobeNewswire News Releases
DURECT to Participate in Upcoming Healthcare Conferences
February 05, 2013
from
PR Newswire
DURECT Announces Positive Results from Relday™ Phase 1 Clinical Trial
January 03, 2013
from
PR Newswire
Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial
January 03, 2013
Plans to Seek Partner and Accelerate Development of Once-Monthly Subcutaneous Formulation of Risperidone for Schizophrenia
Read More
from
GlobeNewswire News Releases
Should Recent Insider Buying on CLNE, DRRX, UGI and CBK Matter to You?
December 18, 2012
from
Marketwired News Releases
DURECT Announces Pricing of Public Offering of Common Stock
December 06, 2012
from
PR Newswire
DURECT to Participate in Upcoming Healthcare Conferences
November 13, 2012
from
PR Newswire
Pain Therapeutics Reports Q3 2012 Financial Results
November 08, 2012
On Track With Financial Guidance for 2012
Read More
from
GlobeNewswire News Releases
DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
November 05, 2012
from
PR Newswire
DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
October 30, 2012
from
PR Newswire
DURECT to Participate in Upcoming Healthcare Conferences
August 21, 2012
from
PR Newswire
DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
August 06, 2012
from
PR Newswire
DURECT Announces Intent to Submit NDA for POSIDUR™ for Post-Operative Analgesia
August 06, 2012
from
PR Newswire
Pain Therapeutics Reports Q2 2012 Financial Results
August 02, 2012
No Change to Financial Guidance for 2012
Read More
from
GlobeNewswire News Releases
DURECT Corporation Invites You to Join its Second Quarter 2012 Earnings Conference Call
July 26, 2012
from
PR Newswire
Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia
July 12, 2012
from
GlobeNewswire News Releases
Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM)
May 30, 2012
Potential First Needle-Free Subcutaneous Treatment Option in $2 Billion Long-Acting Injectable Antipsychotic Market
Read More
from
GlobeNewswire News Releases
Semi-Annual Changes to the NASDAQ Biotechnology Index
May 14, 2012
from
GlobeNewswire News Releases
Pain Therapeutics Reports Q1 2012 Financial Results
May 08, 2012
from
GlobeNewswire News Releases
DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
May 03, 2012
from
PR Newswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here